Skip to main
NDRA

NDRA Stock Forecast & Price Target

NDRA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ENDRA Life Sciences is developing innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which aims to provide cost-effective and precise visualization of liver conditions, particularly Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). The potential FDA approval within the next year is anticipated to drive the stock price significantly higher, supported by a net present value (NPV) analysis indicating substantial upside from the current share price. Additionally, the TAEUS system's capability to enable earlier diagnosis and more accurate monitoring of liver diseases enhances its attractiveness as a transformative tool in the medical diagnostics market.

Bears say

ENDRA Life Sciences Inc. reported a net loss of $1.6 million, translating to an earnings per share (EPS) of $(2.10), which exceeded prior forecasts of $(1.95). The company's financial metrics revealed ongoing challenges, as a subsequent quarter also posted a loss of $1.2 million and an EPS of $(1.71), against estimates of $(2.27). Furthermore, substantial risks were identified, including liquidity concerns, regulatory approval hurdles, commercialization issues, and shifting investor sentiment in the biotech/medtech sectors, all contributing to a fundamentally negative outlook on the stock.

NDRA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ENDRA Life Sciences (NDRA) Forecast

Analysts have given NDRA a Strong Buy based on their latest research and market trends.

According to 1 analysts, NDRA has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ENDRA Life Sciences (NDRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.